• Chemicals
• Discovery / R&D
• Generics
• Market Trends
• Pharma Industry Trends
• Pricing & Reimbursement
• Regulatory
• Sales & Marketing
• Therapeutic

M&A in pharma

Explores the merits of mega-deal in contrast to a more measured portfolio growth strategy

The current market for hormonal contraceptives and infertility drugs is estimated at US$9.4bn, and is forecast to increase by 7% in annual revenues to US$10bn by 2014.

In this report, The Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 - Future Therapies for Birth Control and Reproductive Health  (2^nd Edition) the reader will be introduced to an analysis of current product markets, research and development themes, and company activities within the field.

The report provides insights for product extension and reformulation, sales forecasts to 2018, and allows for assessments of the impact of late-stage pipeline drugs on the market. An overview of R&D programs within the field is also presented showing products from preclinical to premarket authorization phases of development. Therapy area forecasting to 2018 enables the reader to make key assumptions about future markets and prospects, and utilize the data for proprietary predictive market modelling.

Key findings of the report include

• The worldwide market for hormonal contraceptives is estimated at US$6.9bn in 2011, but is expected to decrease approximately 19.5% in annual revenues to US$5.5bn by 2018.
• Drivers of growth for the hormonal contraception sector will be novel transdermal and intravaginal products that offer greater efficacy, lower dosing, and improved and longer control over menstruation.
• Currently, there are over 40 pipeline candidates for female and male contraception.
• The current worldwide market for infertility drugs is US$2.5bn; however the infertility therapy sector is underserved with drugs that are mainly focused on female infertility that induce ovulation for assisted conception programs.
• Market leaders in the infertility sector include Merck Serono, Merck & Co., and Ferring with estimated revenues for their infertility products in 2011 at US$955m, US$625m and US$550m, respectively.  
• Drivers of growth will be through innovation to: reduce side effects associated with pituitary-gonadal drugs; enhance qualitative and quantitative aspects of ovulation and spermatogenesis; and improve overall fertilization and pregnancy-birth rates.
• The male and female infertility R&D area is poorly served with only 15 pipeline candidates identified as potential clinical candidates.

Questions answered by this report include:

• Which contraceptives and infertility drugs are the current and potential future market leaders 
• What impact new drug approvals will have on the reproductive medicine drug market
• Which premarket drugs are identified as high-value products
• Which companies are developing hormonal contraceptives and infertility drugs
• Sales predictions to 2018 for leading contraceptives and infertility drugs  
• How will newcomers affect the product positioning of market leaders  
• What are niche market opportunities in reproductive medicine
• What the future outlook holds for hormonal contraceptives and infertility pharmacotherapies
• How companies are expanding the global reproductive medicine market through sophisticated reformulations and secondary indications for endocrinological and gynaecological disorders
• Which molecules and compounds are main R&D clusters in reproductive medicine     

Research Methodology

The contents of this URCH Publishing report are derived from in-depth research-based surveys of the industry and proprietary analytical assessment tools. Source material also comprises the following:

• Company information
• Scientific periodicals
• Personal communication
• Product information
• Trade press articles
• Market analyst data
• News releases                             
• Public information datasets
• Internet-based research
• Conference proceedings
• Library research         
• Medical/pharma associations

Objectives of the Report

The objectives of this report are to provide an in-depth analysis of the global therapeutic market for hormonal contraceptives and infertility drugs. Included in this study are analyses of key therapy areas, R&D programs, and innovating companies and products. It is hoped that the reader will benefit from market forecasts, pooled knowledge of recent industrial activities and events, and from analytical discourse, which is intended to stimulate growth and create new market opportunities.

Executive Summary

Report Highlights
Objectives of the Report

1. Contraception and Infertility: Market Snapshot

Market data synopsis - contraception and infertility
1.1 Reproductive Health Market Overview
1.2 Market Analysis for Contraception and Infertility
1.2.1 Contraception
1.2.2 Infertility

2. Product Market for Hormonal Contraception

2.1 Contraceptive Formulations
2.2 Combined Estrogen-Progestogen Contraceptives
2.3 Progestogen-Only Contraceptives
2.4 Product Market for Hormonal Contraceptives
2.4.1 Bayer Healthcare Pharmaceuticals
2.4.1.1 Key Product and Portfolio Review
2.4.1.2  Pipeline Focus
Contraceptive Patch
Intrauterine device
2.4.1.3  Sales Estimates and Product Market Outlook
2.4.2  Johnson & Johnson
2.4.2.1  Key Product and Portfolio Review
2.4.2.2 Sales Forecasts and Product Market Outlook
2.4.3 Merck & Co
2.4.3.1 Key Product and Portfolio Review
2.4.3.2 Sales Estimates and Product Market Outlook
2.4.4 Pfizer
2.4.4.1 Key Product and Portfolio Review
2.4.4.2 Sales Estimates and Product Market Outlook
2.4.5 Teva Pharmaceutical Industries
2.4.5.1 Key Product and Portfolio Review
2.4.5.2 Pipeline Focus
2.4.5.3 Sales Estimates and Product Market Outlook
Generics Focus - Watson Pharmaceuticals
2.5 Future Considerations and Outlook for the Contraceptive Product Market

3. Product Market for Infertility Drugs

3.1 Overview for Infertility Drugs
3.2 Pharmacotherapies for Infertility
Mechanism of Action of Infertility Pharmacotherapeutics
3.3 Product Market for Infertility Drugs
3.3.1 AstraZeneca
3.3.1.1. Key Product Review
3.3.1.2 Sales Estimates and Product Market Outlook
3.3.2 Ferring
3.3.2.1 Key Product and Portfolio Review
3.3.2.2. Sales Estimates and Product Market Outlook
3.3.3 Merck & Co
3.3.3.1 Key Product and Portfolio Review
3.3.4 Merck Serono
3.3.4.1 Key Product and Portfolio Review
3.3.4.2 Sales Estimates and Product Market Outlook
3.4 Market Outlook for Infertility Pharmacotherapeutics

4. Research and Development in Reproductive Health

4.1 Female Oral Contraception
4.1.1 Transdermal/Transmucosal Contraceptives
4.1.2 Implantable/Injectable Contraceptives
4.2 Male Contraception
4.3 Contraception - Research and Development Overview
4.4 Infertility Drugs in Research and Development
4.4.1 Female Infertility
4.4.2 Male Infertility
6.3.2.1 Infertility - Research and Development Overview

Reference Sources

List of Tables

Research Methodology
Table 1.1 Estimated Global Sales (US$m) & Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2011-2018
Table 2.1 Selection of Hormonal Contraceptives Segmented by Formulation and Delivery Route, 2011
Table 2.2 Bayer's Hormonal Contraceptive Product Portfolio, 2011
Table 2.3 Bayer`s Pipeline Contraceptive Candidates, 2011
Table 2.4 Estimated Sales (US$) and Annual Growth (%) of Bayer's Leading Hormonal Contraceptive Products, 2011-2018
Table 2.5 Johnson & Johnson`s Hormonal Contraceptive Product Portfolio, 2011
Table 2.6 Estimated Sales (US$m) and Annual Growth (%) of Johnson & Johnson`s Leading Hormonal Contraceptive Products, 2011-2018
Table 2.7 Merck & Co's Hormonal Contraceptive Product Portfolio, 2011
Table 2.8 Estimated Sales (US$m) and Annual Growth (%) of Merck & Co's Leading Hormonal Contraceptive Products, 2011-2018
Table 2.9 Pfizer`s Hormonal Contraceptive Product Portfolio, 2011
Table 2.10 Estimated Sales (US$m) and Annual Growth (%) of Pfizer`s Leading Hormonal Contraceptive Products, 2011-2018
Table 2.11 Teva`s Hormonal Contraceptive Product Portfolio, 2011
Table 2.11 Teva`s Hormonal Contraceptive Product Portfolio, 2011 (continued)
Table 2.12 Estimated Sales (US$m) and Annual Growth (%) of Teva`s Leading Hormonal
Table 3.1 Pharmacotherapies for Infertility, 2011
Table 3.2 Ferring`s Infertility Product Portfolio, 2011
Table 3.3 Estimated Global Sales (US$m) and Annual Growth (%) of Ferring`s Infertility Products, 2011-2018
Table 3.4 Merck & Co.`s Hormonal Infertility Product Portfolio, 2011
Table 3.5 Estimated Global Sales (US$m) and Annual Growth (%) of Merck & Co.'s Hormonal Infertility Products, 2011-2018
Table 3.6 Merck Serono`s Hormonal Infertility Product Portfolio, 2011
Table 3.7 Estimated Global Sales (US$m) and Annual Growth (%) of Merck Serono`s Hormonal Infertility Products, 2011-2018
Table 4.1 Female Oral Contraceptives in Development, 2011
Table 4.1 Female Oral Contraceptives in Development, 2011 (continued)
Table 4.2 Transdermal/Transmucosal Female Contraceptives in Development, 2011
Table 4.3 Implantable/Injectable Female Contraceptives in Development, 2011
Table 4.4 Male Contraceptives in Development, 2011
Table 4.5 Drugs in Development for Female Infertility, 2011
Table 4.6 Drugs in Development for Male Infertility, 2011

List of Figures

Figure 1.1 Estimated Sales (US$m) and Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2011-2018
Figure 1.2 Estimated Global Market Share for Hormonal Contraceptives and Infertility Drug Sectors, 2011 & 2018
Figure 2.1 Global Revenue Trends for Bayer's Leading Hormonal Contraceptive Products, 2005-2010
Figure 2.2 Global Revenue Trends for Johnson & Johnson's Leading Hormonal Contraceptive Products, 2005-2010
Figure 2.3 Global Revenue Trends for Merck & Co's Leading Hormonal Contraceptive Products, 2005-2010
Figure 2.4 Global Product Sales for Pfizer's Hormonal Contraceptive Franchise, 2005-2010
Figure 2.5 Global Sales Trends of Teva's Leading Hormonal Contraceptive Products, 2005-2010
Figure 2.6 Leading Hormonal Contraceptive Products by Sales Revenue (US$m), 2011 (estimated)
Figure 3.1 Global Sales Trends of Merck & Co.'s Leading Hormonal Infertility Products, 2005-2010
Figure 3.2 Global Sales Trends of Merck Serono's Leading Hormonal Infertility Products,
Figure 3.3 Leading Hormonal Infertility Products by Sales Revenue (US$m), 2011 (estimated)